Deucravacitinib, a Tyrosine Kinase 2 Inhibitor, in Systemic Lupus Erythematosus: A Phase II, Randomized, Double‐Blind, Placebo‐Controlled Trial

por Morand, Eric, Pike, Marilyn, Merrill, Joan T., van Vollenhoven, Ronald, Werth, Victoria P., Hobar, Coburn, Delev, Nikolay, Shah, Vaishali, Sharkey, Brian, Wegman, Thomas, Catlett, Ian, Banerjee, Subhashis, Singhal, Shalabh
Publicado 2022

Nivolumab improved survival vs dacarbazine in patients with untreated advanced melanoma

por Long, Georgina V, Atkinson, Victoria, Ascierto, Paolo A, Brady, Benjamin, Dutriaux, Caroline, Maio, Michele, Mortier, Laurent, Hassel, Jessica C, Rutkowski, Piotr, McNeil, Catriona, Kalinka-Warzocha, Ewa, Savage, Kerry J, Hernberg, Micaela, Lebbé, Celeste, Charles, Julie, Mihalcioiu, Catalin, Chiarion-Sileni, Vanna, Mauch, Cornelia, Schmidt, Henrik, Schadendorf, Dirk, Gogas, Helen, Horak, Christine, Sharkey, Brian, Waxman, Ian M, Robert, Caroline
Publicado 2015